Is Arrowhead Pharmaceuticals Inc (ARWR) overvalued? · rev $829.4M
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
This page asks whether Arrowhead Pharmaceuticals Inc (ARWR) looks expensive on cached numbers — not a short thesis.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
ARWR currently screens at market cap $10.59B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ARWR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ARWR stock page for the full model, not this heading.
Not investment advice.